Cytokine storm induced by SARS-CoV-2

Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, New Engl. J. Med., 8, 727, 10.1056/NEJMoa2001017 World Health Organization, Coronavirus disease (COVID-2019) situation reports, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/, 2020 (accessed 15 May 2020). National Health Commission of the People’s Republic of China, Outbreak report, http://www.nhc.gov.cn/xcs/yqtb/202005/d2059dd74f8e4e469c1ad3fb6cf0e3af.shtml/, 2020 (accessed 15 May 2020). Gralinski, 2020, Return of the coronavirus: 2019-nCoV, Viruses, 2 Wang, 2020, Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures, J. Med. Virol. Liu, 2020, The reproductive number of COVID-19 is higher compared to SARS coronavirus, J. Travel Med. Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China JAMA Intern. Med., 10.1001/jamainternmed.2020.0994 Peiris, 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, Lancet, 9371, 1767, 10.1016/S0140-6736(03)13412-5 Nassar, 2018, Middle east respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics, Eur. Rev. Med. Pharmacol. Sci., 15, 4956 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet (London, England), 10223, 497, 10.1016/S0140-6736(20)30183-5 Chan, 2013, Tracing the SARS-coronavirus, J. Thoracic Dis., S118 De Wilde, 2018, Host factors in coronavirus replication, Curr. Top. Microbiol. Immunol., 1–42 Schoeman, 2019, Coronavirus envelope protein: current knowledge, Virology J., 1, 69, 10.1186/s12985-019-1182-0 Masters, 2006, The molecular biology of coronaviruses, Adv. Virus Res., 193–292, 10.1016/S0065-3527(06)66005-3 Fehr, 2015, Coronaviruses: an overview of their replication and pathogenesis, Methods Mol. Biol., 1–23, 10.1007/978-1-4939-2438-7_1 Cui, 2019, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol., 3, 181, 10.1038/s41579-018-0118-9 Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 10.1038/s41586-020-2951-z Xu, 2020, Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV, Viruses, 2 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med., 10.1056/NEJMoa2002032 Shi, 2020, Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study, Lancet Infect. Dis., 4, 425, 10.1016/S1473-3099(20)30086-4 Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiology, 10.1001/jamacardio.2020.1017 Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention, JAMA, 323, 1239, 10.1001/jama.2020.2648 Du, 2020, Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study, Am. J. Respir. Crit. Care Med., 10.1164/rccm.202003-0543OC Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585 Geng, 2020, Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019, Cardiovascular pathology : the official journal of the Society for, Cardiovasc. Pathol., 10.1016/j.carpath.2020.107228 Liu, 2020, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Science China, Life Sci. Huang, 2020, Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis, Travel Med. Infect. Dis., 101606 Zhang, 2020, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy, 10.1111/all.14238 Gu, 2005, Multiple organ infection and the pathogenesis of SARS, J. Exp. Med., 3, 415, 10.1084/jem.20050828 Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thrombosis Haemostasis : JTH, 4, 844, 10.1111/jth.14768 Ding, 2003, The clinical pathology of severe acute respiratory syndrome (SARS): a report from China, J. Pathol., 3, 282, 10.1002/path.1440 Liu, 2020, Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV, J. Med. Virol. Tian, 2020, Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer, J. Thorac. Oncol., 10.1016/j.jtho.2020.02.010 Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, The Lancet Respiratory Med., 8, 420, 10.1016/S2213-2600(20)30076-X Su, 2020, Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China, Kidney Int., 10.1016/j.kint.2020.04.003 Batlle, 2020, Acute kidney injury in COVID- 19: emerging evidence of a distinct pathophysiology, J. Am. Soc. Nephrology: JASN, 10.1681/ASN.2020040419 Xu, 2020, Liver injury during highly pathogenic human coronavirus infections, Liver Int.: Official J. Int. Assoc. Study Liver, 5 Medzhitov, 2007, Recognition of microorganisms and activation of the immune response, Nature, 7164, 819, 10.1038/nature06246 Lim, 2013, Toll-like receptor signaling, Cold Spring Harb Perspect Biol., 1 Meylan, 2006, Intracellular pattern recognition receptors in the host response, Nature, 7098, 39, 10.1038/nature04946 Tisoncik, 2012, Into the eye of the cytokine storm, Microbiol. Mol. Biol. Rev.: MMBR, 1, 16, 10.1128/MMBR.05015-11 Tanaka, 2014, IL-6 in inflammation, immunity, and disease, Cold Spring Harbor Perspect. Biol., 10 Tanaka, 2016, Immunotherapeutic implications of IL-6 blockade for cytokine storm, Immunotherapy, 8, 959, 10.2217/imt-2016-0020 Wang, 2007, Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway, Virus Res., 1–2, 1, 10.1016/j.virusres.2007.02.007 Ward, 1998, Chemokines: understanding their role in T-lymphocyte biology, Biochem. J., 457–70 Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 10.1016/j.cell.2020.02.052 Forni, 2017, Molecular evolution of human coronavirus genomes, Trends Microbiol., 1, 35, 10.1016/j.tim.2016.09.001 Wen, 2020, Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2, J. Infect., 10.1016/j.jinf.2020.02.027 Donoghue, 2000, A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9, Circ. Res., 5, E1 Smits, 2010, Exacerbated innate host response to SARS-CoV in aged non-human primates, PLoS Pathog., 2 Cao, 2020, Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations, Cell Discovery, 10.1038/s41421-020-0147-1 C. Y, G. Y, P. Y, Z.Z.J. Biochemicalb.r. Communications, Structure analysis of the receptor binding of 2019-nCoV, 2020. Kuba, 2005, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat. Med., 8, 875, 10.1038/nm1267 Imai, 2005, Angiotensin-converting enzyme 2 protects from severe acute lung failure, Nature, 7047, 112, 10.1038/nature03712 Li, 2018, CX3CL1/CX3CR1 axis contributes to angiotensin II-induced vascular smooth muscle cell proliferation and inflammatory cytokine production, Inflammation, 3, 824, 10.1007/s10753-018-0736-4 Zhang, 2017, Angiotensin II-induced early and late inflammatory responses through NOXs and MAPK pathways, Inflammation, 1, 154, 10.1007/s10753-016-0464-6 Haga, 2008, Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry, Proc. Natl. Acad. Sci. U. S. A., 22, 7809, 10.1073/pnas.0711241105 Chen, 2019, Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome, Frontiers Microbiol., 50, 10.3389/fmicb.2019.00050 Allen, 2009, The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA, Immunity, 4, 556, 10.1016/j.immuni.2009.02.005 Fernandes-Alnemri, 2007, The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation, Cell Death Differ., 9, 1590, 10.1038/sj.cdd.4402194 Shi, 2017, Pyroptosis: gasdermin-mediated programmed necrotic cell death, Trends Biochem. Sci., 4, 245, 10.1016/j.tibs.2016.10.004 Man, 2017, Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases, Immunol. Rev., 1, 61, 10.1111/imr.12534 Fink, 2006, Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages, Cell. Microbiol., 11, 1812, 10.1111/j.1462-5822.2006.00751.x Pandolfi, 2016, Key role of DAMP in inflammation, cancer, and tissue repair, Clin. Therapeutics, 5, 1017, 10.1016/j.clinthera.2016.02.028 De Wit, 2016, SARS and MERS: recent insights into emerging coronaviruses, Nat. Rev. Microbiol., 8, 523, 10.1038/nrmicro.2016.81 Channappanavar, 2016, Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice, Cell Host Microbe, 2, 181, 10.1016/j.chom.2016.01.007 Narayanan, 2008, Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells, J. Virol., 9, 4471, 10.1128/JVI.02472-07 Siu, 2014, Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain, Cell. Mol. Immunol., 2, 141, 10.1038/cmi.2013.61 Channappanavar, 2017, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin. Immunopathol., 5, 529, 10.1007/s00281-017-0629-x Zhang, 2006, Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals, J. Med. Virol., 1, 1, 10.1002/jmv.20499 Liu, 2019, Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection, JCI Insight, 4, 10.1172/jci.insight.123158 Fu, 2020, Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools, Virologica Sinica, 10.1007/s12250-020-00207-4 Tetro, 2020, Is COVID-19 receiving ADE from other coronaviruses?, Microbes Infect., S1286–4579, 30034 Auyeung, 2005, The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study, J. Infection, 2, 98, 10.1016/j.jinf.2004.09.008 Zumla, 2016, Coronaviruses - drug discovery and therapeutic options, Nat. Rev. Drug Discovery, 5, 327, 10.1038/nrd.2015.37 Blazek, 2015, IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production, J. Exp. Med., 6, 845, 10.1084/jem.20140995 Hoehl, 2020, Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China, The New Engl. J. Med., 13, 1278, 10.1056/NEJMc2001899 Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res., 3, 269, 10.1038/s41422-020-0282-0 Sheahan, 2020, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat. Commun., 1, 222, 10.1038/s41467-019-13940-6 Gao, 2020, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends, 1, 72, 10.5582/bst.2020.01047 Yao, 2020, Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis.: An Official Publ. Infect. Dis. Soc. Am., 10.1093/cid/ciaa237 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 105949 Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, The New Engl. J. Med., 19, 1787, 10.1056/NEJMoa2001282 Zhu, 2020, Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19, J. Infection, 10.1016/j.jinf.2020.03.060 Y. Furuta, T. Komeno, T. Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 7 (2017) 449–463. Cai, 2020, Experimental treatment with favipiravir for COVID-19: An open-label control study, Engineering (Beijing China) Zhang, 2020, Clinical trial analysis of 2019-nCoV therapy registered in China, J. Med. Virol. Xu, 2020, Management of corona virus disease-19 (COVID- 19): the Zhejiang experience, Zhejiang da xue xue bao. Yi xue ban =, J. Zhejiang Univ. Med. Sci., 1 Bloch, 2020, Deployment of convalescent plasma for the prevention and treatment of COVID-19, J. Clin. Investig., 10.1172/JCI138745 Fleming, 2020, Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement, J. Clin. Virology: The Official Publ. Pan Am. Soc. Clin. Virology, 10.1016/j.jcv.2020.104388 Shen, 2020, Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma, JAMA, 10.1001/jama.2020.4783 Ashour, 2020, Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks, Pathogens (Basel, Switzerland), 3, E186 Seif, 2020, JAK inhibition as a new treatment strategy for patients with COVID-19, Int. Arch. Allergy Immunol., 1–9 Wurfel, 2008, Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis, Am. J. Respir. Crit. Care Med., 7, 710, 10.1164/rccm.200803-462OC